Niagen Bioscience (NAGE) Other Non-Current Liabilities (2011 - 2020)
Niagen Bioscience (NAGE) posted quarterly Other Non-Current Liabilities of $250000.0 for Q2 2020, down 14.68% year-over-year from $293000.0 in Q3 2019, and up 5.04% quarter-over-quarter from $238000.0 in Q1 2020.
Powered by 
Analysis
Niagen Bioscience (NAGE) Other Non-Current Liabilities (2011 - 2020) Analysis & Trends
Niagen Bioscience (NAGE) has reported Other Non-Current Liabilities for 8 consecutive years, with $250000.0 the latest figure, recorded in Q2 2020.
- In Q2 2020, Other Non-Current Liabilities fell 14.68% year-over-year to $250000.0; the TTM figure through Jun 2020 stood at $250000.0 (down 14.68% YoY), while the FY2019 annual figure was $169000.0, down 38.55% from the prior year.
- Other Non-Current Liabilities rose to $250000.0 in Q2 2020 per NAGE's latest filing, from $238000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $503850.0 in Q3 2017 and bottomed at $155000.0 in Q3 2018.
- Historically, Other Non-Current Liabilities has averaged $286329.8 across 5 years, with a median of $275000.0 in 2018.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities slumped 63.28% — and 2019, when it jumped 79.7%.
- Niagen Bioscience's Other Non-Current Liabilities stood at $389010.0 in 2016, then slipped by 19.28% to $314000.0 in 2017, then slipped by 12.42% to $275000.0 in 2018, then plunged by 38.55% to $169000.0 in 2019, then soared by 47.93% to $250000.0 in 2020.
- Business Quant data shows NAGE's Other Non-Current Liabilities at $250000.0 in Q2 2020, $238000.0 in Q1 2020, and $169000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 250,000.00 |
| Mar 31, 2020 | 238,000.00 |
| Dec 31, 2019 | 169,000.00 |
| Sep 30, 2019 | 261,000.00 |
| Jun 30, 2019 | 293,000.00 |
| Mar 31, 2019 | 363,000.00 |
| Dec 31, 2018 | 275,000.00 |
| Sep 30, 2018 | 155,000.00 |
| Jun 30, 2018 | 185,000.00 |
| Mar 31, 2018 | 202,000.00 |
| Dec 30, 2017 | 314,000.00 |
| Sep 30, 2017 | 321,119.00 |
| Jul 1, 2017 | 503,850.00 |
| Apr 1, 2017 | 399,010.00 |
| Dec 31, 2016 | 389,010.00 |
| Oct 1, 2016 | 277,615.00 |
| Jan 2, 2016 | 272,002.00 |
| Mar 30, 2013 | 314,468.00 |
| Dec 29, 2012 | 310,267.00 |
| Sep 29, 2012 | 257,004.00 |